López-Salvio YM, Herrera-Rodríguez LJ, Guzmán-Silahua S, Nava-Zavala AH, Rubio-Jurado B

Language: Spanish
References: 43
Page: 12-22
PDF size: 234.43 Kb.

ABSTRACT

D-dimer is the final product of the fibrin degradation which is used as an indicator of plasma coagulation and fibrinolytic system. Currently D dimmer testing is considered as a conventional scrutiny of deep vein thrombosis and the pulmonary embolism. The causes of thrombotic process can be inherited or acquired. In the inherited group we can found clotting factor mutation (factor V Leiden G1691a mutation), prothrombin gen 20210A mutation and endogenous anticoagulant deficiency (protein C, S and antithrombin III). Among the acquired factors is mainly the presence of autoimmune, cancer and obesity diseases, pregnant and surgery. In recent years there has described the activation of the coagulation cascade and the fibrinolysis detectable by the presence of positive D dimer in others pathologies different than deep vein thrombosis and thromboembolism, for example: aortic dissection, ischemic heart disease, stroke, infertility, pregnancy, metabolic diseases, and others. By the foregoing it can be concluded that the D dimer is a standard test for deep vein thrombosis and thromboembolism and it can be a predictor of biological activity of coagulation and fibrinolysis systems in some diseases. These diseases can be grouped into inflammatory processes, autoimmunity and vascular damage; D dimer can also be an auxiliary in the take decision on thromboprophylaxis and time of antithrombotic therapy in these diseases.

REFERENCES

1. Wakai A, Gleeson A, Winter D. Role of fibrin D-dimer testing in emergency medicine. Emerg Med J. 2003; 20 (4): 319-325.

2. Bockenstedt P. D-dimer in venous thromboembolism. N Engl J Med. 2003; 349(13): 1203-1204.

3. Beck WS. Hematology. 5th ed. Cambridge Massachusetts: Massachusetts Institute of Technology; 1991.

4. Dahlbäck B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med. 2005; 257: 209-223.

5. Aird WC. Coagulation. Crit Care Med. 2005; 33 (12): 485-487.

6. Frenette PS, Wagner DD. Adhesion molecules--Part II: Blood vessels and blood cells. N Engl J Med. 1996; 335 (1): 43-45.

7. Ware JA, Heistad DD. Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions. N Engl J Med. 1993; 328 (9): 628-635.

8. Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM et al. Wintrobe’s clinical hematology. 10th ed. Canada: Lippincott Williams & Wilkins; 1999.

9. Izaguirre-Ávila R. Centenario de la doctrina de la coagulación sanguínea. Arch Cardiol Méx. 2005; 75 (Suppl 3): 118-129.

10. Orfeo T, Butenas S, Brummel-Ziedins KE, Mann KG. The tissue factor requirement in blood coagulation. J Biol Chem. 2005; 280 (52): 42887-4296.

11. Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med. 2005; 353 (10): 1028-1040.

12. Rosenberg RD, Aird WC. Vascular-bed--specific hemostasis and hypercoagulable states. N Engl J Med. 1999; 340 (20): 1555-1564.

13. Bauer KA. Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin Thromb Hemost. 2002; 28 Suppl 2: 15-24.

14. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001; 344 (16): 1222-1231.

15. Mangiafico RA, Sarnataro F, Mangiafico M, Fiore CE. Impaired cognitive performance in asymptomatic peripheral arterial disease: relation to C-reactive protein and D-dimer levels. Age Ageing. 2006; 35 (1): 60-65.

16. Johnson CM, Mureebe L, Silver D. Hypercoagulable states: a review. Vasc Endovascular Surg. 2005; 39 (2): 123-133.

17. Voetsch B, Loscalzo J. Genetic determinants of arterial thrombosis. Arterioscler Thromb Vasc Biol. 2004; 24 (2): 216-229.

18. Bick RL. Cancer-associated thrombosis. N Engl J Med. 2003; 349 (2): 109-111.

19. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002; 346 (10): 752-763.

20. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 1999; 341 (11): 801-806.

21. Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003; 349 (13): 1227-1235.

22. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126 (3 Suppl): 401S-428S.

23. Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med. 2007; 356 (14): 1438-1444.

24. Ginsberg JS. Management of venous thromboembolism. N Engl J Med. 1996; 335 (24): 1816-1828.

25. Fedullo PF, Tapson VF. Clinical practice. The evaluation of suspected pulmonary embolism. N Engl J Med. 2003; 349 (13): 1247-1256.

26. Goldhaber SZ. Pulmonary embolism. N Engl J Med. 1998; 339 (2): 93-104.

27. Uresandi F, Blanquer J, Conget F, de Gregorio MA, Lobo JL, Otero R et al. Guía para el diagnóstico, tratamiento y seguimiento de la tromboembolia pulmonar. Arch Bronconeumol. 2004; 40 (12): 580-594.

28. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997; 337 (10): 688-698.

29. Hlavac M, Cook J, Ojala R, Town I, Beckert L. Latex-enhanced immunoassay d-dimer and blood gases can exclude pulmonary embolism in low-risk patients presenting to an acute care setting. Chest. 2005; 128 (4): 2183-2189.

30. Bautista-Bautista EG, Gutiérrez-Fajardo P, Ramírez A, Hernández-Hernández J. Diagnóstico de la tromboembolia pulmonar. Gac Med Mex. 2007; 143 (S1): 19-24.

31. Froehling DA, Elkin PL, Swensen SJ, Heit JA, Pankratz VS, Ryu JH. Sensitivity and specificity of the semiquantitative latex agglutination D-dimer assay for the diagnosis of acute pulmonary embolism as defined by computed tomographic angiography. Mayo Clin Proc. 2004; 79 (2): 164-168.

32. Grau E, Tenías JM, Soto MJ, Gutierrez MR, Lecumberri R, Pérez JL et al. D-dimer levels correlate with mortality in patients with acute pulmonary embolism: Findings from the RIETE registry. Crit Care Med. 2007; 35 (8): 1937-1941.

33. Mora S, Rifai N, Buring JE, Ridker PM. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation. 2006; 114 (5): 381-387.

34. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation. 2001; 103 (19): 2323-2327.

35. Tzoulaki I, Murray GD, Price JF, Smith FB, Lee AJ, Rumley A et al. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. Am J Epidemiol. 2006; 163 (4): 334-341.

36. Rudnicka AR, Rumley A, Lowe GD, Strachan DP. Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. Circulation. 2007; 115 (8): 996-1003.

37. Marcus AJ, Broekman MJ, Pinsky DJ. COX inhibitors and thromboregulation. N Engl J Med. 2002; 347 (13): 1025-1026.

38. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354 (16): 1706-1717.

39. Delgado P, Alvarez-Sabín J, Abilleira S, Santamarina E, Purroy F, Arenillas JF et al. Plasma d-dimer predicts poor outcome after acute intracerebral hemorrhage. Neurology. 2006; 67 (1): 94-98.

40. Frost SD, Brotman DJ, Michota FA. Rational use of D-dimer measurement to exclude acute venous thromboembolic disease. Mayo Clin Proc. 2003; 78 (11): 1385-1391.

41. Roitt IM, Brostoff J, Male D. Inmunología. 5a edición. España: Ed. Mosby; 2000.

42. Abbas AK, Lichtman AH, Pillai S. Inmunología celular y molecular. 4a edición. Ed. McGraw-Hill; 2002.

43. Chunilal SD, Brill-Edwards PA, Stevens PB, Joval JP, McGinnis JA, Rupwate M et al. The sensitivity and specificity of a red blood cell agglutination D-dimer assay for venous thromboembolism when performed on venous blood. Arch Intern Med. 2002; 162 (2): 217-220.